Efflux and uptake transporters as determinants of statin response
The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Abstract
IMPORTANCE OF THE FIELD: The important role of drug transporters in drug absorption and disposition has been well documented. Statins are subjected to active transport of membrane proteins of the superfamilies ATP-binding cassette and solute carrier, and there is limited understanding of the mechanisms by which differences in transporter expression and activity contributes to variability of pharmacokinetics (PKs)/pharmacodynamics (PDs) of statins. AREAS COVERED IN THIS REVIEW: This review aims to discuss the roles of drug transporters in the PKs and PDs of statins, and in drug interactions with statins. WHAT THE READER WILL GAIN: A comprehensive summary of the literature on this subject including in vitro and in vivo observations. TAKE HOME MESSAGE: In vivo and in vitro studies have shown that efflux and uptake transporters modulate the PKs/PDs of statins. Until now organic anion transporting polypeptides (OATP)1B1 variants have been considered major factors in limiting the uptake of statins and increasing statin exposure, and, consequently, increasing risk of myopathy. Further studies in pharmacogenetics and in vitro models to assess statin disposition and toxicity are required to understand the contribution of others transporters, such as multidrug resistance-associated protein (MRP)1, MRP2, breast cancer resistance protein, OATP2B1, OAT1B3 and OATP1A2, in interindividual variability to statins efficacy and safety.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While genetic testing in patients with statin myopathy has not yet become commonplace, there are some clear genetic signals, with variants of genes encoding drug transporters in both the liver and skeletal muscle that increase serum statin concentration linked to muscle side effects (see Supplementary material online, Table S5).106–109”
From Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management (2015) · cites this paper as [107]
Citations
Cites
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043 · cited 1×
“Indeed, SLCO1B1*5 allele was associated with increased risk of statin-induced myopathy in a genome-wide association study in patients taking simvastatin 80 mg [75].”
BackgroundMutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency
Brooks-Wilson, A., Marcil, M., Clee, S. M., Zhang, L.-H., Roomp, K., van Dam, M., Yu, L., Brewer, C., Collins, J. A., Molhuizen, H. O. F., et al. (1999) · Nature Genetics · doi:10.1038/11905 · Cited by 1,687 · cited 1×
“The integral role of ABCA1 in foam cell formation is exemplified by the loss of function mutation causing Tangier disease, characterized by a significant accumulation of cholesterol in macrophages, reduced HDL cholesterol in serum, as well as increased risk of cardiovascular disease [21,22].”
BackgroundBerge, K. E., Tian, H., Graf, G. A., Yu, L., Grishin, N. V., Schultz, J., Kwiterovich, P., Shan, B., Barnes, R., & Hobbs, H. H. (2000) · Science · doi:10.1126/science.290.5497.1771 · Cited by 1,648 · cited 1×
“Mutations in either ABCG5/ 8 cause a rare genetic disorder called sitosterolemia with elevated plasma levels of plant sterols and low level of excretion into the bile [58].”
BackgroundThompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463
Leslie, E. M., Deeley, R. G., & Cole, S. P. C. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.10.012 · Cited by 1,406 · cited 1×
“These transporters act to limit the access of drugs to protected tissue compartments, and to eliminate drugs and metabolites via bile [4].”
BackgroundWang, N., Lan, D., Chen, W., Matsuura, F., & Tall, A. R. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403506101 · Cited by 1,061 · cited 3×
“The integral role of ABCA1 in foam cell formation is exemplified by the loss of function mutation causing Tangier disease, characterized by a significant accumulation of cholesterol in macrophages, reduced HDL cholesterol in serum, as well as increased risk of cardiovascular disease [21,22].”
BackgroundControl of cellular cholesterol efflux by the nuclear oxysterol receptor LXRα
Venkateswaran, A., Laffitte, B. A., Joseph, S. B., Mak, P. A., Wilpitz, D. C., Edwards, P. A., & Tontonoz, P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.200367697 · Cited by 1,005 · cited 8×
“ABC transporter G1 (ABCG1) facilitates cholesterol efflux from macrophages to HDL [17].”
BackgroundInfluentialDrug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
NEUVONEN, P., NIEMI, M., & BACKMAN, J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.003 · Cited by 859 · cited 1×
“In addition, statin therapy is frequently associated with fibric acid agents that are inhibitors of SLCO transporters and CYP 3A4 enzyme [7], resulting in increased circulating statin concentration associated with the risk of myotoxicity [8].”
BackgroundLeier, I., Jedlitschky, G., Buchholz, U., Cole, S. P., Deeley, R. G., & Keppler, D. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)46856-1 · Cited by 853 · cited 4×
“(2010) 6(5) 623 of ABCB1 and CYP3A4 1.9- (atorvastatin lactone) to 3.0-fold (cerivastatin acid) and 2.6- (atorvastatin lactone) to 4.4-fold (cerivastatin acid), respectively, although no significant inductive effects of atorvastatin acid, pravastatin acid, pravastatin lactone, rosuvastatin acid and simvastatin acid we…”
BackgroundInfluentialBrugts, J. J., Yetgin, T., Hoeks, S. E., Gotto, A. M., Shepherd, J., Westendorp, R. G. J., de Craen, A. J. M., Knopp, R. H., Nakamura, H., Ridker, P., et al. (2009) · BMJ · doi:10.1136/bmj.b2376 · Cited by 792 · cited 1×
“They are highly efficacious drugs not only in reducing total and low density lipoprotein (LDL) cholesterol, but also in reducing the risk of atherosclerotic cardiovascular disease [1].”
Background
Research works printed but not linked: 5
- Wang CY, 2007, Arch Med Sci, 3, S91
- Yvan-Charvet L, 2007, J Clin Invest, 117, 3900
- 10.1016/j.taap.2004.10.012 · DOI · Paper page
- Niemi M, 2006, Genomics, 16, 801
- 10.1080/00498250500136676 · DOI
Cited by
Stroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv043 · Cited by 1,443
Recent advances in polymeric transdermal drug delivery systems
Sabbagh, F., & Kim, B. S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.11.025 · Cited by 368
Myotoxicity of statins: Mechanism of action
du Souich, P., Roederer, G., & Dufour, R. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.029 · Cited by 161
Mechanisms of statin-associated skeletal muscle-associated symptoms
Bouitbir, J., Sanvee, G. M., Panajatovic, M. V., Singh, F., & Krähenbühl, S. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.010 · Cited by 136
Kell, D. B., Dobson, P. D., Bilsland, E., & Oliver, S. G. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.11.008 · Cited by 154
Metadata
- Authors
- Rodrigues, A. C.
- Affiliations
- Universidade de São Paulo (BR)
- Corresponding author
- Rodrigues, Alice C
- ORCID
- Rodrigues, Alice C
- Venue
- Expert Opinion on Drug Metabolism & Toxicology
- Publisher
- Informa UK Limited
- Published
- 2010-04-05
- Volume
- 6
- Issue
- 5
- Pages
- 621-632
- ISSN
- 1742-5255 (ISSN-L)
- 1744-7607
- OpenAlex
- W2094858401
- Cited by
- 64
- References
- 100
- Citations by year
- 2024: 1 · 2023: 2 · 2022: 1 · 2021: 3 · 2020: 4 · 2019: 3 · 2018: 6 · 2017: 5 · 2016: 3 · 2015: 5 · 2014: 4 · 2013: 7 · 2012: 6
- FWCI
- 4.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Drug Metabolism & Toxicology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Keywords
- statins, drug transporters, efflux pumps, uptake transporters, pharmacokinetics, pharmacodynamics, drug interactions, OATP1B1, MRP1, MRP2, ABCG2, OATP2B1, OATP1A2, ABC transporters, solute carrier transporters, interindividual variability, statin-induced myopathy, pharmacogenetics
- MeSH terms
- Animals, Hypolipidemic Agents, Drug Interactions, Humans, ATP-Binding Cassette Transporters, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Membrane Transport Proteins, Organic Anion Transporters, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efflux and uptake transporters as determinants of statin response. https://app.cochat.ai/papers/10.1517/17425251003713519
- The paper
- Rodrigues, A. C. (2010). Efflux and uptake transporters as determinants of statin response. Expert Opinion on Drug Metabolism & Toxicology. https://doi.org/10.1517/17425251003713519
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.